Lilly's 'triple G' retatrutide aces crucial obesity trial
Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.
Infex chases after Insmed with bronchiectasis trial win
UK biotech Infex is in hot pursuit of Insmed's Brinsupri, the only approved therapy for non-CF bronchiectasis, with its quarterly-dosed antibody.
Bayer gets swift review for Kerendia in type 1 diabetes
FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.
Novo Nordisk fight with KBP Bio will go to arbitration
Singapore court keeps an asset freeze on KBP Bio, saying the merits of its dispute with Novo Nordisk over a licensing deal must go to arbitration.
Remepy's hybrid Parkinson's therapy poised for phase 3
Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes
6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions